Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2009

View Archived Issues

Captisol-Enabled budesonide/azelastine combination nasal spray effective, convenient

Novel diacylglycerol acyltransferase type 1 inhibitors developed by AstraZeneca

Takeda describes novel substituted pyrazole derivatives for cancer treatment

Cortex Pharmaceuticals claims novel bicyclic amides that enhance synaptic responses

Bristol-Myers Squibb presents novel glucokinase activators

Lilly presents novel substituted piperazinyl pyrazines and pyridines as 5-HT7 receptor antagonists

Allos submits NDA to FDA for pralatrexate in relapsed or refractory PTCL

Poniard completes patient enrollment in phase III SPEAR clinical trial of picoplatin in SCLC

Endo initiates offer to purchase its 6.25% convertible senior notes due 2009

Galapagos advances GLPG-0259 into the clinic for rheumatoid arthritis

Takeda applies for additional indication in Japan for Takepron in gastric and duodenal ulcers

E.U. accepts for review The Medicines Company's MAA for Cleviprex in acute hypertension

Oxygen Biotherapeutics adds Israeli clinical trial sites to phase II study of Oxycyte in TBI

FDA accepts for filing and review Spectrum's sNDA for Fusilev in colorectal cancer

VGX completes phase I multiple ascending-dose study of VGX-1027

HemaQuest receives orphan medicinal designations for hemoglobin disorders

Lux Biosciences reports results from Luveniq phase III LUMINATE trials in uveitis

Akela and Nventa to merge

Biotie initiates clinical trial with proprietary VAP-1 antibody in psoriasis

AMP-activated protein kinase regulator may be useful for the treatment of metabolic disorders

Novel beta3-adrenergic receptor agonists with increased selectivity discovered

Potent and efficacious PI3 kinase inhibitors identified for cancer treatment

Parvovirus H-1PV shows potential in pancreatic ductal adenocarcinoma therapy

Cubist initiates phase II ecallantide trial for blood loss reduction during surgery

Osiris discontinues enrollment in Crohn's study due to concerns with trial design

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...